At the 2026 Science of Skin Summit, Allergan Aesthetics, an AbbVie company, presented its latest research on aging, regenerative aesthetics, and exosome-based skincare. The company introduced the FACTS Principles, a scientific framework by SkinMedica® to ensure consistent evaluation of exosome skincare products, focusing on formulation, stability, safety, and clinical evidence. This initiative aims to promote transparency and rigorous scientific standards in the emerging field of exosome skincare, which holds promise for skin longevity and biological function. Allergan's R&D leaders also shared insights from over 25 years of research and numerous clinical studies, emphasizing evidence-based innovation in skincare.
Following Allergan Aesthetics' presentation at the 2026 Science of Skin Summit, AbbVie Inc (ABBV) shares show stability on Pluang, priced at USD 261.69 with no change in the last day as of Sep 15, 2026 19:14 WIB. The stock remains close to its 52-week high of USD 265.97, reflecting steady investor interest in AbbVie's health sector innovations.
AbbVie announced that the FDA has granted Breakthrough Therapy Designations (BTDs) for its investigational drug Temab-A (telisotuzumab adizutecan) in treating colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Temab-A, a next-generation ...
AbbVie's stock performance shows that investors who bought shares during periods of market pessimism, such as after the Allergan selloff in 2019, earned higher returns than those who bought on positive drug approval news. For example, buying AbbVie a...
The Phase 3 EPCORE DLBCL-2 trial showed that adding epcoritamab, a bispecific antibody, to standard R-CHOP therapy significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with intermediate to...
